Quick Answer
ENDRA Life Sciences Inc. reported Operating Income Loss of -$5.76 million for the year ending 2025.
- ENDRA Life Sciences Inc. showed an increase of +46.7% in Operating Income Loss from 2024 to 2025.
- This data is from ENDRA Life Sciences Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: -$373.5 thousand | Q2 2016: -$494.3 thousand | Q3 2016: -$605.1 thousand | Q1 2017: -$360.7 thousand | Q2 2017: -$1.06 million | Q3 2017: -$910.9 thousand | Q1 2018: -$2.84 million | Q2 2018: -$1.82 million | Q3 2018: -$2.36 million | Q1 2019: -$2.75 million | Q2 2019: -$2.33 million | Q3 2019: -$2.64 million | Q1 2020: -$3.10 million | Q2 2020: -$2.89 million | Q3 2020: -$3.26 million | Q1 2021: -$2.58 million | Q2 2021: -$3.20 million | Q3 2021: -$2.65 million | Q1 2022: -$2.86 million | Q2 2022: -$3.57 million | Q3 2022: -$3.42 million | Q1 2023: -$2.94 million | Q2 2023: -$2.99 million | Q3 2023: -$3.13 million | Q1 2024: -$2.78 million | Q2 2024: -$2.23 million | Q3 2024: -$1.51 million | Q1 2025: -$1.47 million | Q2 2025: -$1.30 million | Q3 2025: -$1.37 million.
- Over the full 10 years of available data (2016 to 2025), ENDRA Life Sciences Inc.'s Operating Income Loss has declined by 221.6%.
- Historical annual values: Fiscal year 2025: -$5.76 million | Fiscal year 2024: -$10.82 million | Fiscal year 2023: -$10.52 million | Fiscal year 2022: -$13.16 million | Fiscal year 2021: -$11.50 million | Fiscal year 2020: -$11.50 million | Fiscal year 2019: -$10.84 million | Fiscal year 2018: -$9.02 million | Fiscal year 2017: -$4.63 million | Fiscal year 2016: -$1.79 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: